TLDR: EVERSANA has launched EVERSANA ORCHESTRATE PV, an advanced AI-driven solution designed to significantly enhance and accelerate pharmacovigilance workflows. This new platform streamlines critical processes like literature monitoring and aggregate reporting, promising increased speed, accuracy, and efficiency while reducing manual labor and costs for the life sciences industry.
CHICAGO – July 17, 2025 – EVERSANA, a prominent global provider of commercial services to the life sciences sector, today announced a significant advancement in pharmaceutical operations with the introduction of EVERSANA ORCHESTRATE PV. This unified, AI-propelled solution is set to transform pharmacovigilance workflows, including literature monitoring and aggregate authoring and reporting, by delivering unparalleled speed, accuracy, and quality across the drug safety landscape.
EVERSANA ORCHESTRATE PV is engineered to automate and customize workflows, ensuring scalability and efficiency. The company reports that the solution has been proven to accelerate the operations lifecycle by as much as 50 percent, while simultaneously reducing manual labor investment by up to 40 percent.
Jim Lang, CEO of EVERSANA, emphasized the company’s commitment to integrating artificial intelligence into pharmaceutical processes. “We remain as committed as ever to ‘pharmatize AI.’ Today we bring pharmacovigilance leaders the long-overdue intelligent, scalable solution to complex and costly PV workflows,” stated Lang. He added, “Through the power of our ORCHESTRATE operating system, our best-in-class experts in drug safety, and rapidly evolving AI-solutions, we’re streamlining safety processes, ensuring global compliance, and helping influence better patient outcomes.”
A key component of EVERSANA ORCHESTRATE PV is its global, multi-language literature monitoring platform. Developed in collaboration with Quantiphi, an AI-first digital engineering company, this platform accelerates monitoring five times faster than current industry standards. It boasts an impressive 99.8 percent accuracy rate and seamlessly integrates with leading drug safety literature platforms such as Oracle Argus Cloud, PubMed, and Embase, fostering unification across all processes.
The aggregate authoring and reporting platform within EVERSANA ORCHESTRATE PV automates the generation of essential regulatory reports, including the Periodic Adverse Drug Experience Report (PADER). This automation, coupled with AI capabilities, saves an average of 30 minutes per report, reduces human error by 90%, and ensures an overall accuracy of 99%, thereby providing actionable insights.
Asif Hasan, Co-founder of Quantiphi, highlighted the collaborative effort: “Together with EVERSANA, we are applying the full potential of AI and Generative AI to some of the most critical challenges in life sciences. We’re reimagining pharmacovigilance processes and operations, helping clients accelerate innovation, reduce risk and drive sustainable value at scale through GenAI.”
Also Read:
- FDA Unveils ‘Elsa’ AI Tool, Promising Accelerated Regulatory Approvals
- Major Pharmaceutical Companies Mark AI Adoption as Immediate Priority, Driving Increased Investment
This launch follows EVERSANA’s recent introduction of EVERSANA ORCHESTRATE MLR in April 2025, another AI-powered solution designed to enhance the medical, legal, and regulatory review process, further solidifying EVERSANA’s mission to leverage AI for industry-wide transformation. The company’s integrated solutions are rooted in the patient experience, spanning all stages of the product lifecycle to deliver long-term, sustainable value for various stakeholders.
